Recent Reports Reflect How the FDA Props Up the Cigarette Trade

Two reports reveal the FDA's role in sustaining cigarette sales in the US. The Goldman Sachs report highlights declining cigarette sales and the rise of cheaper alternatives like modern oral tobacco. The FDA's restrictions have led to the growth of unregulated vape products. The Barclays report shows cigarettes remain highly profitable, hindering the adoption of safer alternatives. To hasten a smoke-free future, public health strategies should align with consumer preferences and embrace harm reduction options. Urgent FDA policy changes are needed to promote innovation and offer smokers better access to reduced-risk products, ultimately displacing cigarettes from the market.